The most recent drugs approved by the European Medicines Agency (2015–2021) for the treatment of breast cancer (including HER2-targeted drugs, CDK 4/6 inhibitors, PIK3CA inhibitors, PARP inhibitors, immunotherapy drugs and antibody–drug conjugates (ADCs)) were recently reviewed by Duranti et al. [10]. This evidence concerns the gene ERBB2 and breast carcinoma.